GLP1R and Obesity: Supporting these data, other glucagon/GLP-1 receptor co-agonists have been reported to lower plasma concentrations of TG and cholesterol (Clemmensen et al., 2014), decrease hepatic fat content (Henderson et al., 2016), and reduce adipose mass in rodent models of T2D and obesity (Evers et al., 2017; Zhou et al., 2017).